Navigation Links
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Date:9/3/2009

PHILADELPHIA, September 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD. Although the mechanism of action is unknown, INTUNIV is thought to directly engage receptors found in the prefrontal cortex - an area of the brain that has been linked in preclinical research to ADHD. Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioral inhibition, and enhance impulse control.

"Shire is proud to introduce INTUNIV, providing clinicians, patients, and their families with a novel ADHD treatment option," said Mike Cola, President of Shire Specialty Pharmaceuticals. "This is a complex disorder in which patients may present with multiple symptoms and behaviors that can be disruptive. INTUNIV expands the Shire ADHD portfolio with a nonscheduled medication, allowing clinicians to optimize their overall approach toward managing ADHD and may help provide symptom control for children and teens with ADHD who often have difficulty responding appropriately to everyday situations and challenges."

Once-daily INTUNIV is expected to be available in US pharmacies in November and will come in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg). INTUNIV will be marketed in the United States by the existing Shire ADHD sales team
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:12/19/2014)... Dec. 18, 2014 Since last month,s FBI ... now known as the leading online black market for ... growth in its offering of drugs and other illegal ... the takedowns did succeed in lowering the numbers of ... of the markets in August. But some new sites ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... 15, 2007 - SIGA Technologies, Inc.,(NASDAQ: SIGA) announced ... guinea pig trial of its lead Lassa fever ... Level 4 conditions at,the U.S. Army Medical Research ... under the supervision of Dr.,Mary Guttieri, who has ...
... lead to hospitalization and drug withdrawal, CHICAGO, May ... hundreds,of migraine patients and physicians commissioned by the ... that,20 percent of migraine patients are currently taking ... have,not been approved by the U.S. Food and ...
Cached Medicine Technology:SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
(Date:12/22/2014)... December 22, 2014 Super Saturday, the ... this year as the busiest day in the 2014 ... The Grass Station had a steady pre-Christmas stream of ... this past Saturday. , “I definitely intend to take ... a Denver resident who was enjoying The Grass Station’s ...
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... Farmers Branch, TX (PRWEB) December 22, 2014 ... the revolutionary work glove with many useful features. Customers ... savings and can have the new gloves delivered to ... manufactures work gear and hand tools that incorporate heavy ... Pro Utility Magnetic Glove allows workers to store metal ...
Breaking Medicine News(10 mins):Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... took substances without approval , , MONDAY, March 3 ... frequently abused prescription drugs increases the risk of drug ... Sean Esteban McCabe asked 3,639 college students, average age ... four classes of prescription drugs -- opioids, stimulants, sleeping ...
... a clear association, but no such link for depression , , ... can help bring on a stroke may have merit, British ... different groups according to how severe their stress is, someone ... a 40 percent increased risk of stroke than someone in ...
... YORK, March 3 With New York physicians,facing a ... to a projected premium increase, an expected one thousand ... the Egg, Empire State,Plaza, on Tuesday, March 4th where ... and then march on the Capitol steps by 12:30 ...
... March 3 Emageon Inc.,(Nasdaq: EMAG ), ... hospitals, healthcare networks and imaging facilities announced,today that ... at the,Raymond James 29th Annual Institutional Investors Conference ... Cypress, Orlando, Florida. Emageon will,present on Wednesday, March ...
... Care Problems ... Media Availability Today 5,000 Nurses ... March 3 In an atmosphere that nurses,describe as attempted "intimidation" ... tomorrow to authorize,their bargaining teams to strike the hospital chain for ...
... Protecting State,s,Elderly from Price Gouging, Ensure Safety ... California,seniors who feel price-gouged by providers ... advocates and elected leaders to fight back ... problems with emergency,preparedness. Legislation introduced by Assembly ...
Cached Medicine News:Health News:Non-Medical Use of Prescriptions Linked to Drug Abuse Risk 2Health News:Stress Can Help Trigger Stroke 2Health News:Attention New York: Please Don't Get Sick on March 4th, Your Doctor Will be in Albany for Malpractice Insurance Reform 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 3Health News:'Atria Bills' Get Support From Assisted Living Residents, Family Members, Senior Groups 2
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
A Color-Enhanced Slide Agglutination Test for the Rapid Qualitative and Semi-Quantitative Detection of Rheumatoid Factor in Serum....
Hemagglutination slide test for the qualitative and quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
Medicine Products: